Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.2200 (-0.1%) ($5.2200 - $5.2200) on Wed. Aug. 4, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.36% (three month average) | RSI | 52 | Latest Price | $5.2200(-0.1%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1% a day on average for past five trading days. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) SPLV(-55%) SLV(-24%) XLU(-7%) XLP(-444%) VT(-1%) | Factors Impacting ADMS price | ADMS will decline at least -1.68% in a week (0% probabilities). IWM(39%) IWO(98%) JETS(84%) BLOK(111%) DRIV(32%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.68% (StdDev 3.36%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.03(3.78%) | 10 Day Moving Average | $4.97(5.03%) | 20 Day Moving Average | $5.05(3.37%) | To recent high | -7.1% | To recent low | 4.2% | Market Cap | $148m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |